Ginsenoside Rd: A promising target for ischemia-reperfusion injury therapy (A mini review).
Biomed Pharmacother
; 171: 116111, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38181712
ABSTRACT
Ischemia-reperfusion injury (IRI) represents a prevalent pathological phenomenon. Traditional treatment approaches primarily aim at restoring blood supply to ischemic organs, disregarding the consequent damage caused by IRI. Belonging to the class of protopanaxadiol ginsenosides that are found in Panax ginseng, ginsenoside Rd (GSRd) demonstrates notable safety alongside a diverse range of biological functions. Its active components exhibit diverse pharmacological effects, encompassing anti-inflammatory, anti-tumor, neuroprotective, cardiovascular-protective, and immune-regulatory properties, making it a promising candidate for addressing multiple medical conditions. GSRd shields against I/R injury by employing crucial cellular mechanisms, including the attenuation of oxidative stress, reduction of inflammation, promotion of cell survival signaling pathways, and inhibition of apoptotic pathways. Additionally, GSRd regulates mitochondrial function, maintains calcium homeostasis, and modulates the expression of genes involved in I/R injury. This review seeks to consolidate the pharmacological mechanism of action of GSRd within the context of IRI. Our objective is to contribute to the advancement of GSRd-related pharmaceuticals and provide novel insights for clinicians involved in developing IRI treatment strategies.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Reperfusion Injury
/
Ginsenosides
Limits:
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
2024
Type:
Article
Affiliation country:
China